A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies
This clinical trial is testing a new experimental medicine called ST-067, both by itself and combined with other proven cancer treatments, for people with advanced solid tumors. Researchers want to find the safest and most effective dose to help the body's immune system fight various types of cancer.
You may be able to join if you are 18 or older, have a confirmed advanced cancer in an organ or tissue, and are generally active. However, you cannot join if you have certain heart conditions, active major infections, untreated brain metastases, or other recent cancers.
Participants will receive the study medication either through an injection under the skin or as an infusion into a vein, depending on the study group. You will also be closely monitored by the medical team throughout the process to check your safety and how your body responds to the treatment.
This study is currently recruiting participants at multiple locations across the United States, including sites in Arizona, Colorado, and Connecticut.
- 1Testing a new experimental cancer treatment called ST-067
- 2Open to adults with various types of advanced solid tumors
- 3Currently actively recruiting participants at select medical centers
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.